PCL is a provider of in-vitro diagnostic products and developed a testing kit that can check nasal discharge for the presence of the virus. The kit was first developed using antibodies from China.
PCL claims that its antibody-based detection kit could make a diagnosis within 10 minutes with 85% accuracy. The testing can be done at home, just like a pregnancy test, which indicates that people could test themselves at home without suffering from the stigma and trauma of going to testing centers or clinics to have themselves checked. It also reduces the risk of exposure to other people.
PCL produces both antigen-based (COVID19 Ag Rapid FIA) and antibody-based (COVID19 IgG/IgM Rapid Gold) detection kits. COVID19 Ag Rapid FIA uses human oropharyngeal swabs and deep sputum samples, unlike COVID19 IgG/IgM Rapid Gold that uses fingertip blood samples.
Another difference between COVID19 Ag Rapid FIA and COVID19 IgG/IgM Rapid Gold is that COVID19 Ag Rapid FIA requires a POC FIA Analyzer as a test instrument, whereas COVID19 IgG/IgM Rapid Gold does not require a test instrument. PCL’s antibody-based detection kit has been approved for clinical trials in Korea and also received CE-IVD certification from the EU.
Figure 1 and Figure 2 are the image and procedures for testing with PCL’s COVID19 Ag Rapid FIA and COVID19 IgG/IgM Rapid Gold.
Figure 1. Image of PCL’s COVID19 Ag Rapid FIA and COVID19 IgG/IgM Rapid Gold
Figure 2. Procedures for testing with PCL’s COVID19 Ag Rapid FIA and COVID19 IgG/IgM Rapid Gold